Badel Tomislav, Keros Jadranka, Krapac Ladislav, Pavicin Ivana Savić
Zavod za stomatolosku protetiku, Stomatoloski fakultet Sveucilista u Zagrebu, Zagreb, Hrvatska.
Arh Hig Rada Toksikol. 2010 Sep;61(3):371-80. doi: 10.2478/10004-1254-61-2010-2032.
Bisphosphonate treatment and its aetiopathogenic association with aseptic osteonecrosis of the jaw is one of the more prominent public health issues today. The aim of this review is to see into the mechanisms of bisphosphonate effects on bones described in literature (anti-osteoclastic activity, cytotoxicity, antiangiogenesis, genetic factors, and imbalance between osteoclasts and osteoblasts). Bisphosphonate treatment is the dominant cause of jaw necrosis. Epidemiological data show an exclusive incidence of osteonecrosis of the jaw in patients who took one or a combination of nitrogen-containing bisphosphonates. Risk factors vary by the bisphosphonate potency (particularly risky are the highly potent pamidronate and zoledronate, which are given intravenously), dosage, duration of treatment, and the illness. Jaw necrosis is most common in oncology patients, and only 5 % in patients with osteoporosis. From a dental-medical point of view, a good oral health is important because osteonecrosis often appears after a periodontal or oral surgical procedure.
双膦酸盐治疗及其与颌骨无菌性坏死的病因学关联是当今较为突出的公共卫生问题之一。本综述的目的是探究文献中所描述的双膦酸盐对骨骼的作用机制(抗破骨细胞活性、细胞毒性、抗血管生成、遗传因素以及破骨细胞与成骨细胞之间的失衡)。双膦酸盐治疗是颌骨坏死的主要原因。流行病学数据显示,服用一种或多种含氮双膦酸盐的患者中,颌骨坏死的发病率极高。风险因素因双膦酸盐的效力(静脉注射的高效力帕米膦酸盐和唑来膦酸盐尤其危险)、剂量、治疗持续时间以及疾病而异。颌骨坏死在肿瘤患者中最为常见,而在骨质疏松症患者中仅占5%。从牙医学的角度来看,良好的口腔健康很重要,因为骨坏死通常在牙周或口腔外科手术后出现。